News
Rinvoq is filed in Japan to treat non-radiographic axial spondyloarthritis .- AbbVie
Abbvie has filed its JAK inhibitor Rinvoq (upadacitinib) in Japan for an additional indication of non-radiographic axial spondyloarthritis (nr-axSpA) in adult patients who have responded inadequately to existing treatments.
This submission is supported by data from a multinational Phase III clinical study, including Japan evaluating the drug in adult patients with active nr-axSpA with objective signs of inflammation who had an inadequate response to at least two nonsteroidal anti-inflammatory drugs (NSAIDs), or intolerance to or contraindication for NSAIDs.
Rinvoq is already approved in Japan for the treatment of rheumatoid arthritis, psoriatic arthritis, and atopic dermatitis.
Condition: Axial Spondyloarthritis
Type: drug